SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

Recruiting

Phase 2

SBRT & PembrolizumabSBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

Sponsor:

RTOG Foundation, Inc.

Code:

NCT03546582

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

Stereotactic Body Radiation Therapy (SBRT)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by RTOG Foundation, Inc. on 2025-04-22.